On December 11, 2025, Citigroup analyst Joanne Wuensch provided an update on Haemonetics Corporation (NYSE: HAE), assigning a Neutral rating with a price target of $88. This adjustment comes at a pivotal moment for investors considering the stock’s current price of $87.09, reflecting limited upside potential. As Haemonetics navigates a dynamic market environment, this rating could influence investment strategies moving forward.
Recent Price Action
Haemonetics’ stock has experienced notable volatility in recent trading sessions, reflecting broader market sentiments. The shares currently trading at $87.09 have dipped by approximately 2.84% or $2.48, suggesting a cautious short-term outlook among investors. Volume has also been subdued, with 289,120 shares changing hands compared to an average volume of 976,758, indicating a potential lack of conviction in this price range. Over the past year, the stock has fluctuated between a 52-week high of $97.97 and a low of $84.21, evidencing a relatively stable price range but with room for further movement given the current market conditions. With a beta of 0.3, HAE is perceived as less volatile than the broader market, potentially appealing to risk-averse investors.
Historical Performance
Haemonetics has delivered a mixed performance across various time frames. Over the past 30 days, the stock surged by 23.67%, significantly outperforming broader market averages and indicating robust interest from buyers. In the quarterly view, HAE has shown an impressive rise of 62.98%. Conversely, the stock’s yearly performance stands at 8.05%, suggesting that while recent trends are positive, the stock has struggled to maintain momentum over a more extended period. The average weekly volatility is recorded at 2.54%, and the monthly volatility is slightly higher at 2.88%. This performance underscores the stock’s potential for significant movements, which should be monitored by active investors.
Earnings Analysis
In its most recent earnings report dated November 6, 2025, Haemonetics surpassed analysts’ expectations with an earnings per share (EPS) of $1.27, significantly exceeding estimates of $1.12. This surprise of approximately 13.39% reflects strong underlying business performance and a solid operational execution. This positive trend follows a previous report from August, where EPS was $1.1 against an estimate of $1.01, resulting in an 8.91% surprise. Such consistent outperformance suggests that Haemonetics might be on a steady growth trajectory, which is an encouraging sign for prospective investors.
Consensus Ratings
The consensus from analysts following Haemonetics is predominantly positive. The stock has garnered a total of eight ratings, with seven classified as Buy and one as Hold, and no Sell ratings identified. The average price target recently set by analysts stands at $83.5, while Citigroup’s new target of $88 indicates a slight uptick in expected performance. The highest price target within this group is $90, showcasing a bullish sentiment from several analysts, while the lowest is $64, which could suggest the potential for downside risk should market conditions shift unfavorably. Overall, this distribution reflects confidence among many analysts in Haemonetics’ prospects.
Stock Grading or Fundamental View
Haemonetics currently holds a Stocks Telegraph Grade (ST Score) of 56, which places it in a moderate bracket. This grading incorporates a multidimensional analysis of its financial health and market positioning. A score above 50 generally suggests that the company possesses favorable fundamentals, although it may not fully demonstrate the competitive advantages often associated with higher-rated stocks. Investors should assess this rating in conjunction with other factors, especially given the evolving landscape in the health technology sector.
Conclusion
For investors considering Haemonetics Corporation (HAE), the recent neutral rating from Citigroup emphasizes a watchful yet cautious approach. Given the stock’s impressive short-term gains but mixed long-term performance, it is best suited for those leaning towards moderate growth strategies rather than aggressive investments. Potential investors should remain vigilant regarding broader market conditions and company-specific developments that could impact stock performance. Though the recent earnings surprise adds to its appeal, the cautious rating signals that a balanced assessment of risks and rewards is critical when engaging with this stock.